Reference health
Cannabinoids for Treatment of MS Symptoms: State of the Evidence
38/38 checkable references clean · checked 2026-07-22
Every reference with a DOI in the deposited reference list resolved to a known work in Crossref or DataCite at the dated check, and none carried a retraction, withdrawal, or removal notice.
10 without a DOI — not checked. A reference deposited without a DOI is never matched by title or guessed at; it stays outside the checked set, and this line discloses that.
The 38 checked references that resolve
resolves10.1111/add.12508
Cross‐sectional and prospective relation of cannabis potency, dosing and smoking behaviour with cannabis dependence: an ecological study
resolves10.1038/sj.ijo.0803272
The pharmacology of cannabinoid receptors and their ligands: an overview
resolves10.1212/WNL.0000000000000363
Systematic review: Efficacy and safety of medical marijuana in selected neurologic disorders [RETIRED]
resolves10.1001/jama.2015.6613
Cannabinoid Dose and Label Accuracy in Edible Medical Cannabis Products
resolves10.1212/WNL.0000000000000250
Summary of evidence-based guideline: Complementary and alternative medicine in multiple sclerosis
resolves10.1191/1352458504ms1085oa
Prevalence and treatment of spasticity reported by multiple sclerosis patients
resolves10.1191/026921599677595404
A review of the properties and limitations of the Ashworth and modified Ashworth Scales as measures of spasticity
resolves10.1016/S0140-6736(03)14738-1
Cannabinoids for treatment of spasticity and other symptoms related to multiple sclerosis (CAMS study): multicentre randomised placebo-controlled trial
resolves10.1136/jnnp.2005.070136
Cannabinoids in multiple sclerosis (CAMS) study: safety and efficacy data for 12 months follow up
resolves10.1136/jnnp-2012-302468
MUltiple Sclerosis and Extract of Cannabis: results of the MUSEC trial
resolves10.1191/1352458504ms1082oa
Do cannabis-based medicinal extracts have general or specific effects on symptoms in multiple sclerosis? A double-blind, randomized, placebo-controlled study on 160 patients
resolves10.1111/j.1468-1331.2006.01639.x
Randomized controlled trial of cannabis‐based medicine in spasticity caused by multiple sclerosis
resolves10.1179/016164109X12590518685660
A double-blind, randomized, placebo-controlled, parallel-group study of Sativex, in subjects with symptoms of spasticity due to multiple sclerosis
resolves10.1111/j.1468-1331.2010.03328.x
A randomized, double-blind, placebo-controlled, parallel-group, enriched-design study of nabiximols* (Sativex<sup>®</sup>), as add-on therapy, in subjects with refractory spasticity caused by multiple sclerosis
resolves10.1016/j.pain.2012.12.002
Prevalence and natural history of pain in adults with multiple sclerosis: Systematic review and meta-analysis
resolves10.1073/pnas.92.8.3376
Mast cells express a peripheral cannabinoid receptor with differential sensitivity to anandamide and palmitoylethanolamide.
resolves10.1212/01.wnl.0000176753.45410.8b
Randomized, controlled trial of cannabis-based medicine in central pain in multiple sclerosis
resolves10.1111/pme.12569
Nabilone as an Adjunctive to Gabapentin for Multiple Sclerosis-Induced Neuropathic Pain: A Randomized Controlled Trial
resolves10.1016/j.jpain.2012.10.009
Low-Dose Vaporized Cannabis Significantly Improves Neuropathic Pain
resolves10.1016/j.jpain.2007.12.010
A Randomized, Placebo-Controlled, Crossover Trial of Cannabis Cigarettes in Neuropathic Pain
resolves10.1111/j.1365-2125.2011.03970.x
Cannabinoids for treatment of chronic non‐cancer pain; a systematic review of randomized trials
resolves10.1007/s11481-015-9600-6
Cannabinoids for the Treatment of Chronic Non-Cancer Pain: An Updated Systematic Review of Randomized Controlled Trials
resolves10.1016/j.jpain.2015.07.014
Cannabis for the Management of Pain: Assessment of Safety Study (COMPASS)
resolves10.1136/bmj.325.7374.1199
Self reported cannabis use as a risk factor for schizophrenia in Swedish conscripts of 1969: historical cohort study
resolves10.1016/j.jad.2016.02.007
A literature review and meta-analyses of cannabis use and suicidality
resolves10.1212/WNL.0b013e318212ab0c
Effects of cannabis on cognitive function in patients with multiple sclerosis
resolves10.1161/JAHA.113.000638
Cannabis Use: Signal of Increasing Risk of Serious Cardiovascular Disorders
resolves10.1007/s11883-017-0663-0
What is the Current Knowledge About the Cardiovascular Risk for Users of Cannabis-Based Products? A Systematic Review
resolves10.1111/j.1360-0443.1996.tb02264.x
Cannabis: pharmacology and toxicology in animals and humans
The 10 references without a DOI — listed, not checked
no DOI — not checkedAmericans for Safe Access. Legal Information By State & Federal Law.
http://www.safeaccessnow.org/state_and_federal_law
. Accessed 15 Sept 2017.
no DOI — not checkedMARINOL [package insert]. North Chicago, IL: AbbVie Inc.
no DOI — not checkedCESAMET [package insert]. Somerset, New Jersey: Meda Pharmaceuticals Inc.
no DOI — not checkedGW Pharmaceuticals. Sativex prescriber Information.
https://www.gwpharm.com/products-pipeline/sativex/prescriber-information-full
. Accessed Sept 15, 2017.
no DOI — not checkedInternational Association for Cannabinoids Medicines. Cannador.
https://cannabis-med.org/index.php?tpl=def&id=241&lng=en&red=deflist
. Accessed 15 Sept 2017.
no DOI — not checkedFu, et al. A mixed treatment comparison on efficacy and safety of treatments for spasticity caused by multiple sclerosis: a systematic review and network meta-analysis. Clin Rehabil. 2018;1:269215517745348.
no DOI — not checkedAllen JH, de Moore GM, Heddle R, et al. Cannabinoid hyperemesis: cyclical hyperemesis in association with chronic cannabis abuse. Cut. 2004;53(11):1566–70.
no DOI — not checkedChen J, et al. Cannabinoid hyperemesis syndrome: a result of chronic, heavy cannabis use. Curr Psychiatr. 2013;12(10):48–54.
no DOI — not checkedJones JI, et al. Successful treatment of suspected cannabinoid hyperemesis syndrome using haloperidol in the outpatient setting. Case Rep Psychiatr. 2016;2016(3614053):1–3.
no DOI — not checkedGrotenhermen F, Russo E. Cannabis and cannabinoids: pharmacology, toxicology, and therapeutic potential. Binghamton: The Haworth Press. p. 2002.
What this badge says. CiteStamped means the CHECKABLE references of this
work were clean at the dated check: each resolved to a known work in a public registry, and none
carried a retraction notice at that time. It says nothing about the quality, findings,
or importance of the work itself, and nothing about references deposited without a DOI.
checked 2026-07-22 — re-checked daily as this page is visited; titles and statuses come from Crossref and DataCite and are not part of the signed record
Embed this badge
Both snippets point at the live badge image and link back to this page. The badge re-renders from the daily check, so an embed never goes stale by more than a day of visits.
<a href="https://citestamp.com/citestamped/10.1007/s11910-018-0859-x"><img src="https://citestamp.com/citestamped/10.1007/s11910-018-0859-x/badge.svg" alt="CiteStamped reference-health badge" width="460" height="64"></a>
[](https://citestamp.com/citestamped/10.1007/s11910-018-0859-x)